China on Wednesday released a guideline that lays out a set of ethical rules for human genome editing research.

The guideline was formulated by the medical ethics subcommittee of the National Science and Technology Ethics Committee, according to a statement released on the official website of the Ministry of Science and Technology.

The document prohibits using edited reproductive cells, fertilized eggs, or human embryos for pregnancy or reproduction.

Regarding clinical research involving genome editing of somatic cells — which are cells in the body other than sperm and egg cells, it said that such research should be aimed at preventing or treating diseases and should be carried out after animal tests or preclinical, in vitro experiments have offered basic evidence in safety and efficacy.

In terms of research that carry out genome editing over human embryos or fetal somatic cells, it is necessary to carefully evaluate the risk of potential heritable variations.

The guideline stipulates that risk control and surveillance measures, as well as an adequate amount of supervision from authorities, should be implemented on genome editing research.

When considering transforming research outcomes into practical use, researchers should prioritize the affordability and accessibility of novel technologies, rather than solely focus on market needs.